Hemodialysis complicated with renal anemia
Conditions
Interventions
experimental group:According to the Hb level before the study and the use of recombinant human erythropoietin injection, they were divided into two groups: 1. Recombinant human erythropoietin injectio
2. 4000 IU / time, once a week, intravenous injection 
control group:According to the Hb level before the study and the use of recombinant human erythropoietin injection, they were divided into two groups: 1. Recombinant human erythropoietin injection 200
2. 2000iu / time, 1 branch / time,&
Sponsors
Tongzhou District, Dongzhimen Hospital, Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
32 Years to 78 Years
Inclusion criteria
Inclusion criteria: 1. 100 = 100ng / ml and transferrin saturation >= 10%; 6. Voluntary subjects, patients who have signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with uncontrolled severe hypertension (SP >= 180mmhg, DP >= 110mmhg); 2. Patients with congestive heart failure [New York Heart Association cardiac function grade III or above]; 3. Ast or ALT value > 3 times the upper limit of standard value and ALB 15mg / L 4 weeks before enrollment; 5. Positive occult blood in stool 4 weeks before enrollment; 6. Patients who had undergone surgery with massive bleeding within 3 months before enrollment or who planned to undergo surgery during the clinical trial (except arteriovenous shunt); 7. Patients with malignant tumors (including hematological malignancies), hematological diseases (myelodysplastic syndrome, hemolytic anemia, etc.) or obvious hemorrhagic diseases; 8. Those who have received protein assimilation hormone, testosterone heptanate or methandrone within 3 months; 9. Previous functional organ transplantation or scheduled organ transplantation or no kidney; 10. Past alcohol and drug abusers; 11. Those who are unable to cooperate or unwilling to cooperate due to neurological and mental diseases; 12. Thos e who are allergic to known ingredients of test drug or control drug and allergic constitution or ESAs resistance; 13. Pregnant or lactating women or those with recent birth planning; 14. A history of blood transfusion within 3 months; 15. Participated in other clinical trials in recent 3 months; 16. The researcher believes that there are any other medical conditions that are not suitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hemoglobin; | — |
Countries
China
Contacts
Public ContactLI JIanjun
Tongzhou District, Dongzhimen Hospital, Beijing University of Chinese Medicine
Outcome results
None listed